摘要
目的探讨卡瑞利珠单抗联合化疗治疗在晚期胃癌中的应用效果。方法选取2022年6月—2023年12月徐州医科大学附属医院收治的102例晚期胃癌患者为研究对象,按随机数字表法将其分为对照组和观察组,每组51例。对照组采用常规化疗治疗,观察组在对照组基础上加用卡瑞利珠单抗治疗。比较两组患者的临床疗效、肿瘤标志物、T细胞因子及不良反应发生情况。结果观察组疾病控制率为92.16%,高于对照组的76.47%,差异有统计学意义(P<0.05)。治疗后,观察组糖类抗原199、癌胚抗原、糖类抗原724水平分别为(32.96±3.52)U/mL、(26.63±2.42)ng/mL、(24.63±2.12)U/mL,均低于对照组的(37.28±3.76)U/mL、(31.57±3.69)ng/mL、(28.96±2.43)U/mL,组间差异有统计学意义(P<0.05);观察组白细胞介素-6、白细胞介素-8水平分别为(17.58±1.32)pg/mL、(5.63±1.12)pg/mL,均低于对照组的(19.57±1.34)pg/mL、(7.89±1.14)pg/mL,干扰素-γ水平为(10.69±1.25)pg/mL,高于对照组的(9.15±1.17)pg/mL,组间差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论卡瑞利珠单抗与化疗联合治疗能更好控制晚期胃癌病情,降低肿瘤标志物水平,改善T细胞因子活性,且未增高不良反应发生风险。
Objective To investigate the effect of camrelizumab combined with chemotherapy in the treatment of advanced gastric cancer.Methods A total of 102 patients with advanced gastric cancer admitted to the Affiliated Hospital of Xuzhou Medical University from June 2022 to December 2023 were selected as the research objects,according to the random number table method,they were divided into a control group and an observation group,with 51 cases in each group.The control group was treated with conventional chemotherapy,and the observation group was treated with camrelizumab on the basis of the control group.The clinical efficacy,tumor markers,T cell factor and adverse reactions were compared between the two groups.Results The disease control rate of the observation group was 92.16%,which was higher than 76.47% of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of carbohydrate antigen 199,carcinoembryonic antigen and carbohydrate antigen 724 in the observation group were(32.96±3.52)U/mL,(26.63±2.42)ng/mL and(24.63±2.12)U/mL,respectively,which were lower than(37.28±3.76)U/mL,(31.57±3.69)ng/mL,(28.96±2.43)U/mL of the control group,the differences between the groups were statistically significant(P<0.05);the levels of interleukin-6 and interleukin-8 in the observation group were(17.58±1.32)pg/mL and(5.63±1.12)pg/mL,respectively,which were lower than(19.57±1.34)pg/mL and(7.89±1.14)pg/mL in the control group,the level of interferon-γwas(10.69±1.25)pg/mL,which was higher than(9.15±1.17)pg/mL in the control group,and the differencse between the groups were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Camrelizumab combined with chemotherapy can better control the condition of advanced gastric cancer,reduce the levels of tumor markers,improve the activity of T cell factor,and does not increase the risk of adverse reactions.
作者
葛艳
赵阳
GE Yan;ZHAO Yang(Department of Oncology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221004,China)
出处
《反射疗法与康复医学》
2024年第14期119-122,共4页
Reflexology And Rehabilitation Medicine
